APTITUDE HEALTH®

EPICS

Conference Coverage: ASCO 2024 – Focus on Lung Cancer

Monday, June 10, 2024

Report Contents

EPICS

Meeting Snapshot

EPICS

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE

DATE:
June 10, 2024



DISEASE STATE AND DATA PRESENTATIONS by key experts

INSIGHTS REPORT including postmeeting analyses and actionable recommendations

PANEL: Key experts in lung cancer
- > 6 from US
- > 3 from Europe

LUNG CANCER-SPECIFIC DISCUSSIONS on therapeutic advances and their application in clinical decision-making

Panel Consisting of 6 US and 3 European Lung Cancer Experts

EPICS

Marina Chiara Garassino, MD
University of Chicago

Nasser Hanna, MD
Indiana University School of Medicine

CHAIR:
Corey J. Langer, MD, FACP
University of Pennsylvania

Roy Herbst, MD, PhD
Yale Cancer Center

Benjamin Besse, MD, PhD
Institute Gustave Roussy

Solange Peters, MD, PhD
University Hospital of Lausanne

Ignacio Wistuba, MD
MD Anderson Cancer Center

Mark Socinski, MD
AdventHealth Cancer Institute

Enriqueta Felip, MD, PhD
Vall d'Hebron University Hospital

Meeting Agenda

EPICS

Time (EDT)	Topic	Speaker/Moderator
11.00 AM – 11.05 AM	**Welcome and Introductions**	Corey J. Langer, MD, FACP
11.05 AM – 11.15 AM	**Small Cell Lung Cancer**	Benjamin Besse, MD, PhD
11.15 AM – 11.40 AM	Discussion and Key Takeaways	All faculty
11.40 AM – 11.50 AM	**Targeted Therapy in Stage I–III NSCLC**	Roy Herbst, MD, PhD
11.50 AM – 12.15 PM	Discussion and Key Takeaways	All faculty
12.15 PM – 12.30 PM	**Oncogene-Driven, Stage IV NSCLC: *EGFR/HER2***	Marina Garassino, MD
12.30 PM – 12.45 PM	Discussion and Key Takeaways	All faculty
12.45 PM – 12.55 PM	**Break**	
12.55 PM – 1.10 PM	**Oncogene-Driven, Stage IV NSCLC: *KRAS, MET, ALK***	Mark Socinski, MD; Enriqueta Felip, MD, PhD
1.10 PM – 1.35 PM	Discussion and Key Takeaways	All faculty
1.35 PM – 1.45 PM	**Immunotherapy in Stage I–III NSCLC**	Solange Peters, MD, PhD
1.45 PM – 2.00 PM	Discussion and Key Takeaways	All faculty
2.00 PM – 2.10 PM	**Immunotherapy and Other Approaches in Stage III–IV NSCLC/Subsequent Therapy in Metastatic NSCLC**	Nasser Hanna, MD
2.10 PM – 2.25 PM	Discussion and Key Takeaways	All faculty
2.25 PM – 2.30 PM	**Wrap-Up and Closing Comments**	Corey J. Langer, MD, FACP

APTITUDE HEALTH®

EPICS

Congress Highlights

Small Cell Lung Cancer

ADRIATIC: Durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer (LS-SCLC)

Spigel DR, et al. ASCO 2024. Abstract LBA5

EPICS

DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC) – efficacy and safety analyzed by presence of brain metastasis

Dingemans AM, et al. ASCO 2024. Abstract 8015

EPICS

First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate, in patients with advanced solid tumors

Chandana SR, et al. ASCO 2024. Abstract 3001

EPICS

Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors

Shen L, et al. ASCO 2024. Abstract 3012

EPICS

STUDY POPULATION

- MB088C017 study: MDS patients with ≥10% ring sideroblasts or ≥5% with *SF3B1* mutation, <5% blasts in bone marrow, non-del(5q) MDS, refractory/intolerant to ESAs, or naive, average RBC transfusion burden ≥2 U/8 weeks, no prior treatment with disease-modifying agents (eg, IMIDs, HMAs); randomized to luspatercept (n = 153) or placebo (n = 76). This subanalysis: 99/153 patients who did not achieve RBC transfusion independence (TI) for ≥8 weeks by week 24 but continued treatment through week 48

OUTCOMES

- 58% (n = 11/99) of patients achieved RBC TI for ≥8 weeks
  - 24 hours, 1 patients achieved RBC TI for ≥16 weeks
  - Median time to achieving RBC TI for ≥8 weeks was 3 months

EXPERT CONCLUSIONS

Continuing luspatercept treatment beyond week 24 provides clinical benefit in late responders and decreases the transfusion load in patients.

APTITUDE HEALTH®

EPICS

Key Takeaways

Small Cell Lung Cancer

Small Cell Lung Cancer (1/2)

EPICS

The experts agreed that the ADRIATIC trial set a new standard of care of consolidation durvalumab for patients with LS-SCLC who have

Small Cell Lung Cancer (2/2)

EPICS

While tarlatamab is seen as active in SCLC, the experts described the need for adequate education and facilities to address CRS that

APTITUDE HEALTH®

EPICS

Congress Highlights

Targeted Therapy in Stage I–III NSCLC

Molecular residual disease analysis from the ADAURA trial of adjuvant osimertinib in patients with resected *EGFR*-mutated stage IB–IIIA non-small cell lung cancer

John T, et al. ASCO 2024. Abstract 8005

EPICS

Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated (*EGFR*m) NSCLC: Primary results of the phase 3 LAURA study

Ramalingam SS, et al. ASCO 2024. Abstract LBA4

EPICS

Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors to durvalumab or observation after chemoradiation in unresectable locally-advanced *ALK*+ non-small cell lung cancer

Jayakrishnan R, et al. ASCO 2024. Abstract 8013

EPICS

APTITUDE HEALTH®

EPICS

Key Takeaways

Targeted Therapy in Stage I–III NSCLC

Targeted Therapy in Stage I–III NSCLC (1/2)

EPICS

Expert opinion is that consolidation osimertinib is the standard of care for patients with *EGFR*-mutated, unresectable stage III NSCLC

Targeted Therapy in Stage I–III NSCLC (2/2)

EPICS

Regarding molecular testing of patients with early-stage NSCLC, the pathology expert recommended avoiding large panels, as there

APTITUDE HEALTH®

EPICS

Congress Highlights

Oncogene-Driven, Stage IV NSCLC:
EGFR/HER2

Amivantamab plus lazertinib vs osimertinib in first-line *EGFR*-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study

Felip E, et al. ASCO 2024. Abstract 8504

EPICS

Subcutaneous amivantamab and lazertinib as first-line treatment in patients with *EGFR*-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study

Lim SM, et al. ASCO 2024. Abstract LBA8612

EPICS

Ivonescimab (I) combined with chemotherapy in patients with *EGFR*m non-squamous NSCLC who progressed on EGFR TKI treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial

Zhang L, et al. ASCO 2024. Abstract 8508

EPICS

A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with *EGFR* exon 20 insertion mutations: Primary analysis of WU-KONG1 study

Yang JCH, et al. ASCO 2024. Abstract 8513

EPICS

Trastuzumab deruxtecan (T-DXd) in patients with *HER2*-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02

Janne PA, et al. ASCO 2024. Abstract 8543

EPICS

Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific TKI, in patients with *HER2* aberration-positive solid tumors: Updated phase IA data from Beamion LUNG-1, including PFS data

Heymach J, et al. ASCO 2024. Abstract 8514

EPICS

APTITUDE HEALTH®

EPICS

Key Takeaways

Oncogene-Driven, Stage IV NSCLC:
EGFR/HER2

Oncogene-Driven, Stage IV NSCLC: *EGFR/HER2* (1/2)

EPICS

The experts think the subcutaneous formulation of amivantamab addresses issues related to infusion, although adverse events

Oncogene-Driven, Stage IV NSCLC: *EGFR/HER2* (2/2)

EPICS

The experts still use single-agent osimertinib in most of their patients with newly diagnosed, stage IV NSCLC with an *EGFR* mutation

APTITUDE HEALTH®

EPICS

Congress Highlights

Oncogene-Driven, Stage IV NSCLC:
KRAS, MET, ALK

KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic NSCLC harboring a *KRAS* G12C mutation

Mok TSK, et al. ASCO 2024. Abstract LBA8509

EPICS

Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with *KRAS* G12C-mutant advanced solid tumors

Heist RS, et al. ASCO 2024. Abstract 3007

EPICS

STUDY POPULATION

OUTCOMES

EXPERT CONCLUSIONS

TUMOR RESPONSE IN NSCLC

RESPONSE INDICATORS ACROSS ANALYSIS PERIODS

Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with *KRAS* G12C-mutant advanced NSCLC

Burns TF, et al. ASCO 2024. Abstract 8510

EPICS

Sotorasib plus carboplatin and pemetrexed in *KRAS* G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial

Li BT, et al. ASCO 2024. Abstract 8512

EPICS

KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced *KRAS* G12C mutated NSCLC

Gregorc V, et al. ASCO 2024. Abstract LBA8511

EPICS

Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous *EGFR* wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial

Camidge DR, et al. ASCO 2024. Abstract 103

EPICS

Lorlatinib vs crizotinib in treatment-naïve patients with advanced *ALK*+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study

Solomon BJ, et al. ASCO 2024. Abstract LBA8503

EPICS

APTITUDE HEALTH®

EPICS

Key Takeaways

Oncogene-Driven, Stage IV NSCLC:
KRAS, MET, ALK

Oncogene-Driven, Stage IV NSCLC: *KRAS*, *MET*, *ALK*

EPICS

Most of the experts agreed the CROWN data demonstrated that lorlatinib is the most active agent for patients with *ALK*-rearranged

APTITUDE HEALTH®

EPICS

Congress Highlights

Immunotherapy in Stage I–III NSCLC

Neoadjuvant nivolumab + chemotherapy vs chemo in patients with resectable NSCLC: 4-year update from CheckMate 816

Spicer J, et al. ASCO 2024. Abstract LBA8010

EPICS

Outcomes with perioperative durvalumab in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN

EPICS

Clinical outcomes with perioperative nivolumab by nodal status among patients with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study

Provencio M. et al. ASCO 2024. Abstract LBA8007

EPICS

IMpower010: Final disease-free survival and second overall survival interim results after ≥5 years of follow-up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer

Wakelee HA, et al. ASCO 2024. Abstract LBA8035

EPICS

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial

Blank CU, et al. ASCO 2024. Abstract LBA2

EPICS

APTITUDE HEALTH®

EPICS

Key Takeaways

Immunotherapy in Stage I–III NSCLC

Immunotherapy in Stage I–III NSCLC

EPICS

For a patient who has a pCR after neoadjuvant immunotherapy, the experts would currently not recommend de-escalating treatment after

APTITUDE HEALTH®

EPICS

Congress Highlights

Immunotherapy and Other Approaches in Stage III–IV NSCLC/Subsequent Therapy in Metastatic NSCLC

Updated results from COAST, a phase 2 study of durvalumab ± oleclumab or monalizumab in patients with stage III unresectable non-small cell lung cancer

Aggarwal C, et al. ASCO 2024. Abstract 8046

EPICS

Five-year outcomes with first-line nivolumab + ipilimumab + chemotherapy vs chemotherapy in patients with metastatic NSCLC in CheckMate 9LA

Reck M, et al. ASCO 2024. Abstract 8560

EPICS

Sacituzumab govitecan vs docetaxel in patients with metastatic non-small cell lung cancer previously treated with platinum-based chemotherapy and PD(L)-1 inhibitors: Primary results from the phase 3 EVOKE-01 study

Paz-Ares LG, et al. ASCO 2024. Abstract LBA8500

EPICS

Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases

Mehta MP, et al. ASCO 2024. Abstract 2008

EPICS



APTITUDE HEALTH®

EPICS

Key Takeaways

Immunotherapy and Other Approaches in Stage III–IV NSCLC/Subsequent Therapy in Metastatic NSCLC

Immunotherapy and Other Approaches in Stage III–IV NSCLC/Subsequent Therapy in Metastatic NSCLC

EPICS

Regarding the negative results seen with the addition of durvalumab to CRT in the PACIFIC-2 study, expert opinion is that a major

[redacted]

APTITUDE HEALTH®

US 5901-B Peachtree Dunwoody Road
Suite 415, Atlanta, GA 30328, US

EU Laan van Nieuw Oost-Indië 133 F
2593 BM The Hague, the Netherlands

UK 6th Floor, 2 Kingdom Street
London, W2 6BD, United Kingdom

aptitudehealth.com